Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...

Detaylı Bibliyografya
Asıl Yazarlar:	Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2008

Benzer Materyaller

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Yazar:: Grozinsky-Glasberg, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
Yazar:: King, C, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
Yazar:: Gupta, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Yazar:: Ur, E, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
Yazar:: Su-Chen Li, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
Yazar:: Baldelli Roberto, ve diğerleri
Baskı/Yayın Bilgisi: (2010-03-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
Yazar:: Roberto eBaldelli
Baskı/Yayın Bilgisi: (2014-02-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
Yazar:: Sen Gupta, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
Yazar:: Rihards Saksis, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
Yazar:: Marco Alì, ve diğerleri
Baskı/Yayın Bilgisi: (2015-10-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
Yazar:: Hubina, E, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
Yazar:: Ralf S. Eschbach, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
Yazar:: Chahal, H, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
Yazar:: Cakir, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
Yazar:: Cakir, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
Yazar:: Peter Wiesli, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
Yazar:: Den Gupta, P, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
Yazar:: Grozinsky-Glasberg, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
Yazar:: Chahal, H, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Update on neuroendocrine tumours
Yazar:: Grossman, AB
Baskı/Yayın Bilgisi: (2012)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Yazar:: Sebastian Krug, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
Yazar:: Halfdan Sorbye, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Yazar:: Inbal Uri, ve diğerleri
Baskı/Yayın Bilgisi: (2018-07-01)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
Yazar:: Fernando Sebastian-Valles, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
Yazar:: Sheila D. Rustgi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
Yazar:: Joana Lima Ferreira, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
Yazar:: Ström T, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
Yazar:: Wenjuan Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
Yazar:: Ur, E, ve diğerleri
Baskı/Yayın Bilgisi: (1992)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
Yazar:: Carroll, P, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Growth hormone-releasing peptides (GHRP) and their analogues
Yazar:: Korbonits, M, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
Yazar:: Korbonits, M, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Yazar:: Grozinsky-Glasberg, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Antiangiogenic effects of somatostatin analogues.
Yazar:: García de la Torre, N, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
Yazar:: Pedro Marques, ve diğerleri
Baskı/Yayın Bilgisi: (2019-11-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Yazar:: Jenkins, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)